Rifaximin
- Generic Name
- Rifaximin
- Brand Names
- Xifaxan, Zaxine
- Drug Type
- Small Molecule
- Chemical Formula
- C43H51N3O11
- CAS Number
- 80621-81-4
- Unique Ingredient Identifier
- L36O5T016N
- Background
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...
- Indication
Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...
- Associated Conditions
- Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea
- Associated Therapies
- -
Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD
- Conditions
- Interventions
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2023-02-15
- Target Recruit Count
- 449
- Registration Number
- NCT02498301
- Locations
- 🇺🇸
Tripler Army Medical Center/Schofield Barracks, Honolulu, Hawaii, United States
🇺🇸Naval Medical Center San Diego, San Diego, California, United States
🇺🇸Naval Hospital Camp Lejeune, Camp Lejeune, North Carolina, United States
Rifaximin Use in Severe Alcoholic Hepatitis
- Conditions
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- Saint Vincent's Hospital, Korea
- Target Recruit Count
- 170
- Registration Number
- NCT02485106
Treating Bacterial Overgrowth in Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 4
- Registration Number
- NCT02470780
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial
- Conditions
- Interventions
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Coordinación de Investigación en Salud, Mexico
- Target Recruit Count
- 11
- Registration Number
- NCT02439307
- Locations
- 🇲🇽
Centro Médico Nacional Siglo XXI, Mexico, Ciudad De Mexico, Mexico
Rifaximin Therapy in Chronic Kidney Disease
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Jason Stubbs, MD
- Target Recruit Count
- 38
- Registration Number
- NCT02342639
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
The Effects of Nitazoxanide in Hepatic Encephalopathy
- Conditions
- Interventions
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 36
- Registration Number
- NCT02334163
- Locations
- 🇪🇬
Faculty of medicine, Ain Shams University, Cairo, Egypt
Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02190357
- Locations
- 🇨🇳
Shanghai changzheng Hospital, Shanghai, Shanghai, China
Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Centre Hospitalier Universitaire Saint Pierre
- Target Recruit Count
- 15
- Registration Number
- NCT02163837
- Locations
- 🇧🇪
CHU St Pierre, Brussels, Belgium
Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding
- Conditions
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Hospital General de Mexico
- Target Recruit Count
- 88
- Registration Number
- NCT02158182
- Locations
- 🇲🇽
Hospital General de Mexico, Mexico City, Mexico
Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
- Conditions
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 100
- Registration Number
- NCT02120196
- Locations
- 🇪🇬
Tanta university hospital, Tanta, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.